Otherwise, Di Leo et al. evaluated the value of [TIMP-2]∙[IGFBP7] to predict AKI free days in 719 critically ill patients, estimating an optimal cut-off of 0.37 (ng/ml)2/1000 (AUC 0.633, specificity and sensitivity 56% and 64%, respectively), thereby demonstrating that [TIMP-2]∙[IGFBP7] captures most AKI positive cases and a high number of patients who do not develop AKI21. This evidence concerns the gene TIMP2 and acute kidney injury.